Physician profile
Nancy E Amir
NPI 1568461242
$2,113.94
in general payments reported to CMS, 2019-2025
16 companies · $553 in 2025
The $553 reported for 2025 was more than what 85% of Low Vision Rehabilitation providers received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $17.24 · 2021: $293 · 2022: $221 · 2023: $569 · 2024: $285 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,406.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $318.04 | 2023-2024 | |
| Apellis Pharmaceuticals, INC. | $249.22 | 2024 | Syfovre |
| Astellas Pharma US INC | $243.98 | 2023 | Izervay |
| Abbvie INC. | $223.36 | 2022-2025 | Vuity |
| Optos, INC. | $176.58 | 2019 | |
| Amgen INC. | $154.68 | 2025 | Tepezza |
| Lkc Technologies, INC. | $132.24 | 2025 | |
| Novartis Pharmaceuticals Corporation | $130.12 | 2021 | |
| Dompe US, INC. | $121.86 | 2025 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $87.99 | 2022 | |
| Alcon Vision LLC | $84.62 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $64.28 | 2025 | |
| Glaukos Corporation | $54.34 | 2021 | |
| Oyster Point Pharma, INC. | $31.86 | 2022 | |
| Allergan, INC. | $23.53 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Amir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.